4D Molecular Therapeutics (NASDAQ:FDMT) Coverage Initiated by Analysts at Barclays

Equities researchers at Barclays began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report issued on Wednesday. The firm set an “overweight” rating and a $33.00 price target on the stock. Barclays‘s price objective points to a potential upside of 288.69% from the stock’s previous close.

A number of other brokerages also recently issued reports on FDMT. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Chardan Capital reiterated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, December 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

4D Molecular Therapeutics Trading Up 6.5%

Shares of FDMT stock opened at $8.49 on Wednesday. The company has a market cap of $485.08 million, a P/E ratio of -2.26 and a beta of 2.99. The firm has a fifty day moving average price of $9.08 and a 200 day moving average price of $8.24. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC raised its stake in shares of 4D Molecular Therapeutics by 265.3% during the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock worth $9,524,000 after buying an additional 796,000 shares in the last quarter. Federated Hermes Inc. grew its holdings in 4D Molecular Therapeutics by 33.4% during the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock worth $6,186,000 after acquiring an additional 417,157 shares during the period. Millennium Management LLC grew its holdings in 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares during the period. Parkman Healthcare Partners LLC purchased a new position in 4D Molecular Therapeutics in the third quarter worth $1,738,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in 4D Molecular Therapeutics in the third quarter valued at $1,556,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.